Quartet Medicine, Merck partner

Thursday, January 7, 2016

Quartet Medicine, a biotechnology company focused on the development of novel treatments for chronic pain and inflammation, has entered into a strategic agreement with Merck, known as MSD outside the U.S. and Canada, in connection with Quartet’s pipeline of novel small molecule drugs modulating the tetrahydrobiopterin (BH4) pathway.

[Read More]